1. Pink Sheet

PhRMA Sues To Block HHS Drug Importation Rule Citing Security, Safety, First Amendment Concerns

 
• By Brenda Sandburg

Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.

Pill with Canadian flag wrapped around it and red ball inside
PhRMA seeks to halt rule allowing importation of Rx drugs from Canada • Source: Shutterstock

The Pharmaceutical Research and Manufacturers of America has asked a court to declare invalid the US Department of Health and Human Services’ final rule permitting importation of certain lower-priced prescription drugs from Canada, arguing that it will weaken the drug distribution system, undermine regulatory protections that keep consumers safe, and violate the Constitution.

The complaint, filed 23 November in the US District Court for the District of Columbia, was brought by PhRMA,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 
• By Eliza Slawther

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By Xu Hu

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.